Alzamend Neuro Inc
NASDAQ:ALZN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Alzamend Neuro Inc
NASDAQ:ALZN
|
US |
|
Sidomulyo Selaras Tbk PT
IDX:SDMU
|
ID |
|
I
|
India Motor Parts & Accessories Ltd
NSE:IMPAL
|
IN |
|
P
|
Polyfair Holdings Ltd
HKEX:8532
|
HK |
|
U
|
Uniqure NV
F:UQ1
|
NL |
|
Sumitomo Pharma Co Ltd
TSE:4506
|
JP |
|
B
|
Bright Outdoor Media Ltd
BSE:543831
|
IN |
|
Tsukada Global Holdings Inc
TSE:2418
|
JP |
|
Zhejiang Sunriver Culture Co Ltd
SSE:600576
|
CN |
|
Americann Inc
OTC:ACAN
|
US |
|
C
|
CSH Alliance Bhd
KLSE:CSH
|
MY |
|
L
|
LAI YIH Footware Co Ltd
TWSE:6890
|
KY |
Alzamend Neuro Inc
Alzamend Neuro, Inc. is a preclinical stage biopharmaceutical company, which engages in the manufacture of pharmaceutical products. The company is headquartered in Tampa, Florida and currently employs 2 full-time employees. The company went IPO on 2021-06-15. The firm's pipeline consists of two therapeutic drug candidates: AL001 and AL002. The AL001 is a cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001 or LiProSal, through two royalty-bearing worldwide licenses from the University of South Florida Research Foundation, Inc. (licensor). AL002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as AL002 or CA022W, through a royalty-bearing worldwide license from the licensor.
Alzamend Neuro, Inc. is a preclinical stage biopharmaceutical company, which engages in the manufacture of pharmaceutical products. The company is headquartered in Tampa, Florida and currently employs 2 full-time employees. The company went IPO on 2021-06-15. The firm's pipeline consists of two therapeutic drug candidates: AL001 and AL002. The AL001 is a cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001 or LiProSal, through two royalty-bearing worldwide licenses from the University of South Florida Research Foundation, Inc. (licensor). AL002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as AL002 or CA022W, through a royalty-bearing worldwide license from the licensor.
